Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ProPhase Labs's Enterprise Value is $9.81 Mil.
ProPhase Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-16.45 Mil. Therefore, ProPhase Labs's EV-to-EBIT ratio for today is -0.60.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ProPhase Labs's Enterprise Value is $9.81 Mil.
ProPhase Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.36 Mil. Therefore, ProPhase Labs's EV-to-EBITDA ratio for today is -1.17.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ProPhase Labs's Enterprise Value is $9.81 Mil.
ProPhase Labs's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $4.35 Mil. Therefore, ProPhase Labs's EV-to-Revenue ratio for today is 2.26.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, ProPhase Labs's Enterprise Value is $9.81 Mil.
ProPhase Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.34 Mil. Therefore, ProPhase Labs's EV-to-FCF ratio for today is -1.18.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
ProPhase Labs (OTCPK:PRPH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
ProPhase Labs's current Enterprise Value is $9.81 Mil.
ProPhase Labs's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.45 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
ProPhase Labs's current Enterprise Value is $9.81 Mil.
ProPhase Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.36 Mil.
ProPhase Labs's current Enterprise Value is $9.81 Mil.
ProPhase Labs's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.35 Mil.
ProPhase Labs's current Enterprise Value is $9.81 Mil.
ProPhase Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.34 Mil.
ProPhase Labs's current Enterprise Value is $9.81 Mil.
ProPhase Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs Enterprise Value Related Terms
ProPhase Labs Enterprise Value Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs NSTM, IDTA, IVRO: Enterprise Value Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Enterprise Value distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
ProPhase Labs's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Enterprise Value of $9.81 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ProPhase Labs and its competitors.
Is ProPhase Labs' Enterprise Value too high?
ProPhase Labs' current Enterprise Value is $9.81 Mil.
How does ProPhase Labs' Enterprise Value compare to NSTM and IDTA?
ProPhase Labs' Enterprise Value of $9.81 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current Enterprise Value is $9.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Enterprise Value is $9.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Enterprise Value is $9.81 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 